STAAR Surgical announces $30M buyback and China NMPA approval for EVO+ TICL

STAAR SURGICAL CO

Authorized $30M share repurchase program, expected to run over six months from cash on hand.
Company had $222.8M cash and equivalents, no debt as of March 28, 2025; ~49.5M shares outstanding.
China's NMPA approved EVO+ Toric ICL for myopia correction (-0.5D to -18D, astigmatism ≤6D).
EVO+ spheric ICL application remains pending with NMPA; Switzerland manufacturing validations ongoing for China supply.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.